Q2 EPS Forecast for Ocular Therapeutix Decreased by Analyst

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Equities researchers at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Ocular Therapeutix in a note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($0.37) per share for the quarter, down from their prior forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.48) EPS.

A number of other analysts have also issued reports on OCUL. Royal Bank of Canada started coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target on the stock. Needham & Company LLC decreased their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, William Blair initiated coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

Ocular Therapeutix Price Performance

Shares of NASDAQ:OCUL opened at $7.11 on Thursday. The company has a market cap of $1.13 billion, a P/E ratio of -5.39 and a beta of 1.51. The business has a fifty day simple moving average of $7.46 and a 200-day simple moving average of $8.29. Ocular Therapeutix has a 52 week low of $4.79 and a 52 week high of $11.78. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%.

Hedge Funds Weigh In On Ocular Therapeutix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deep Track Capital LP grew its stake in Ocular Therapeutix by 0.9% during the 4th quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company’s stock valued at $109,622,000 after purchasing an additional 114,822 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Ocular Therapeutix by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company’s stock worth $72,453,000 after buying an additional 99,730 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of Ocular Therapeutix by 43.9% in the fourth quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company’s stock worth $25,073,000 after buying an additional 895,304 shares during the last quarter. Deltec Asset Management LLC raised its holdings in Ocular Therapeutix by 3.8% in the first quarter. Deltec Asset Management LLC now owns 2,716,373 shares of the biopharmaceutical company’s stock valued at $19,911,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in Ocular Therapeutix by 26.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company’s stock valued at $11,398,000 after acquiring an additional 278,610 shares during the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.